EyePoint (EYPT) Income from Non-Controlling Interests (2020 - 2022)
EyePoint (EYPT) posted Income from Non-Controlling Interests of $1000.0 for Q4 2022, down 50.0% sequentially from $2000.0 in Q3 2022, and down 83.33% YoY from $6000.0 in Q4 2021.
Powered by 
Analysis
EyePoint (EYPT) Income from Non-Controlling Interests (2020 - 2022) Analysis & Trends
EyePoint has reported Income from Non-Controlling Interests for 3 years, with the latest figure at $1000.0 in Q4 2022.
- Quarterly Income from Non-Controlling Interests fell 83.33% year-over-year to $1000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $12000.0 (down 47.83% YoY) and the FY2022 annual result came in at $12000.0, down 47.83% from the prior year.
- Income from Non-Controlling Interests slipped to $1000.0 in Q4 2022 per EYPT's latest filing, from $2000.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $7000.0 in Q3 2021 and troughed at $1000.0 in Q4 2022.
- A 3-year average of $3666.7 and a median of $3500.0 in 2020 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2021 and 2022: Income from Non-Controlling Interests soared 250.0% in 2021, then slumped 83.33% in 2022.
- Over 3 years, Income from Non-Controlling Interests stood at $2000.0 in 2020, then surged by 200.0% to $6000.0 in 2021, then plunged by 83.33% to $1000.0 in 2022.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1000.0, $2000.0, and $4000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 5,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 7,000.00 |
| Jun 30, 2021 | 4,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | 3,000.00 |